详细会议介绍参看往期文章： （点击蓝字跳转） 报名开启｜顶流期刊征+2025智能机器人关键技术大会盛会将至！ 展览展示｜抢位2025智能机器人关键技术大会！高曝光商务合作虚位以待，共赴解锁新机遇 9大期刊联合征文｜投稿2025智能机器人关键技术大会，年底正刊发表！ 上半年以来，港股属实"热闹"。机器人相关的企业陆陆续续向港交所递交招股书。近期，像乐动机器人、斯坦德 机器人、兆威机电、仙工智能、埃斯顿、石头科技、卧安机器人等悉数向冲击港股。 6月26日消息， 镁伽科技有限公司（简称"镁伽科技"）正式向港交所递交招股书。 根据招股书披露，此次募资将 主要用于技术及产品研发、扩大产能、拓展销售网络、开展战略合作与投资，以及补充营运资金等一般性公司用 途。 中国机器人技术应用领域领先的自主智能体提供商 镁伽科技成立于2016年，是 中国机器人技术应用领域领先的自主智能体提供商 ，致力于在智慧实验室与智能制造 场景中，为企业提升生产力并推动创新。 依托机器人自动化技术与AI领域感知、构思及执行的专有技术，镁伽科技的多功能自主智能体具备独立完成复杂 任务的能力，让人力得以解放，专注于实验室与制造场景中的高价值任务，助力企 ...

智通财经APP获悉，据港交所6月25日披露，镁伽科技有限公司(下称：镁伽科技)向港交所主板提交上市 申请，摩根士丹利、华泰国际、德意志银行和建银国际为其联席保荐人。 依托机器人技术自动化与AI领域感知、构思及执行的专有技术，该公司的多功能自主智能体擅长独立 完成复杂任务，让人力得以解放，专注于实验室与制造场景中的高价值工作任务，助力企业驾驭智能化 转型，为下一代科研、制造等领域发展做好前瞻布局。 在当今AI驱动的时代，现代科研与制造环境往往需要先进自动化能力和灵活性，以应对复杂多变的工 作流程。传统自动化系统曾经是提高效率的主要方式，现在都在尝试融合AI能力以应对需求，但往往 难以驾驭场景中涌现的海量实时数据。与此形成鲜明对比的是，该公司这类AI原生的自主智能体提供 商，在数据驱动的时代格局中占据先天优势。 根据灼识咨询的资料，全球自主智能体机器人技术市场规模已从2020年约人民币318亿元增长至2024年 约人民币1,143亿元，复合年增长率达37.7%，预计到2030年将达到约人民币3,837亿元。随着各行业向 智能自动化加速转型，潜在市场渗透率仍存巨大空间，尤其在各种智慧实验室与智能制造应用场景，自 主 ...

Financial Data and Key Metrics Changes - Q1 revenue grew 18% year over year to $55.8 million, marking the thirteenth consecutive quarter of exceeding guidance [14][23] - Gross margin improved to 72.1%, a 170 basis point increase year over year [14][26] - Operating income for Q1 was $39,000, an improvement of $1.4 million year over year [28] - Adjusted EBITDA for Q1 was $1 million, improving by $1.4 million year over year [28] Business Line Data and Key Metrics Changes - Record sales in the Medical segment, particularly in MedSpa and plastic surgery, with strong performance in primary therapy [14][24] - Payments revenue continues to grow at more than twice the rate of total revenue, contributing positively to the business [25][82] - Retention metrics remained stable with Net Revenue Retention (NRR) at 98% and Gross Revenue Retention (GRR) at 91% [25] Market Data and Key Metrics Changes - The acquisition of TrueLark expands the addressable market to over $10 billion in the U.S. [7][19] - New integrations launched in Q1 increased the integrated market by approximately 60,000 locations [15] Company Strategy and Development Direction - The acquisition of TrueLark is aimed at enhancing the product roadmap and expanding market opportunities [12][20] - Focus on automating workflows and improving patient engagement through technology [8][12] - Continued investment in R&D and sales/marketing to drive growth and customer acquisition [21][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business amid economic challenges, with no degradation in lead flow or pipeline [50] - Anticipated core business growth in 2025 to outpace 2024, despite a tough year-over-year revenue comparison in Q2 [30][31] - The company remains focused on revenue growth, operational efficiency, and maintaining positive free cash flow [32] Other Important Information - The company ended Q1 with $98.2 million in cash and short-term investments, with plans to use $25 million for the TrueLark acquisition [28] - The acquisition is expected to close in Q2 2025, with performance-based equity awards tied to revenue milestones [19][21] Q&A Session Summary Question: Incremental value of TrueLark to existing bundles - Management highlighted joint customers and the revenue-driving potential of TrueLark, emphasizing its automation capabilities [36][37] Question: Specialty medical growth and hiring plans - Management confirmed strong Q1 performance in specialty medical and anticipated further growth in the back half of the year due to increased sales capacity [40][41] Question: TrueLark's pricing model and monetization opportunities - TrueLark's product is primarily sold on a per-location or per-contract basis, with opportunities for reevaluation of pricing strategies [45][46] Question: Resilience of the pipeline amid economic challenges - Management reported no degradation in pipeline metrics and expressed optimism about the integration of TrueLark enhancing their market position [49][50] Question: Competitive landscape and AI opportunity - Management noted a clear vision for their product roadmap and highlighted TrueLark's established customer base and proven ROI as competitive advantages [55][56] Question: Vertical penetration and economic sensitivity - Management indicated less than 15% penetration across all verticals, with dental being the most penetrated and specialty medical the least [68][71] Question: Customer acquisition cost and go-to-market strategy - Management confirmed ongoing efforts to refine the go-to-market strategy to reduce customer acquisition costs and increase sales velocity [75][76] Question: Payment solution attach rate - Management noted that the payment solution currently makes up less than 10% of revenue but is growing faster than overall revenue [80][81]